IBI is an innovative hi-tech Swiss biomedical company focused on research, development and production of medical devices for tissue engineering and regenerative medicine: substitutes, grafts, 3D matrixes and 2D scaffolds. The company, headquartered in Mezzovico and founded in 2008, has developed a bone substitute called Smartbone.
SmartBone is an innovative bone substitute specifically developed for bone regeneration in oral and maxillofacial reconstructive surgery. It mimics the human bone, is strong and shaping resistant and resistant to screws and surgical fixation manoeuvres.
SmartBone is a new composite bone substitute based on a novel concept of biomaterials assembly: it is obtained combining natural mineral structures with bioactive polymers. During integration with the host, it allows formation of new bone by ingrowth of patients cells into it while biopolymers degrade.
During the last month the company was successful in several areas. In February Agire Invest SA, the Development Agency of the Ministry of Economics of the Canton Ticino, joined IBI shareholders as an Investors. End of May another investor followed: IBI secured a second investment round from Fondazione “Filippo Serpero”.
The next milestone was reached only a few weeks later: end of June SmartBone obtained the CE mark for human use.
0Comments
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines